<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Cytogenetics, molecular genetics, and pathophysiology of myelodysplastic syndromes/neoplasms (MDS)</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Cytogenetics, molecular genetics, and pathophysiology of myelodysplastic syndromes/neoplasms (MDS)</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Cytogenetics, molecular genetics, and pathophysiology of myelodysplastic syndromes/neoplasms (MDS)</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Authors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Yanming Zhang, MD</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Michelle M Le Beau, PhD</a></dd><dt><span> </span>Section Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Richard A Larson, MD</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Alan G Rosmarin, MD</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Jul 20, 2023.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H5771332"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>Myelodysplastic syndromes/neoplasms (MDS) are clonal hematopoietic neoplasms that are characterized by chronic cytopenias accompanied by morphologic dysplasia, with a propensity to progress to bone marrow failure or acute myeloid leukemia (AML). </p><p>Chromosomal and genetic abnormalities are important for diagnosis, classification, prognosis, and treatment of MDS. Specific cytogenetic (chromosomal) abnormalities are detected in one-half of cases, while nearly all cases of MDS have one or more genetic aberrations (eg, mutations, copy number alterations, aberrant gene expression). Most often, the genetic abnormalities are related to epigenetic regulators, RNA-splicing machinery, transcription factors, and/or cytokine signaling pathways. While most gene aberrations in MDS are acquired abnormalities, a minority of cases are associated with germline pathologic gene variants. </p><p>Cytogenetic and genetic features of de novo (primary) MDS are reviewed in this topic. </p><p>Related topics include:</p><p class="bulletIndent1"><span class="glyph">●</span>Definitions, methods of detection, and genetic consequences of cytogenetic abnormalities in various hematologic malignancies. (See  <a class="medical medical_review" href="/d/html/4482.html" rel="external">"General aspects of cytogenetic analysis in hematologic malignancies"</a> and  <a class="medical medical_review" href="/d/html/4490.html" rel="external">"Chromosomal translocations, deletions, and inversions"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Further discussion of prognosis for MDS. (See  <a class="medical medical_review" href="/d/html/15775.html" rel="external">"Prognosis of myelodysplastic neoplasms/syndromes (MDS) in adults"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Cytogenetic abnormalities in AML. (See  <a class="medical medical_review" href="/d/html/4544.html" rel="external">"Acute myeloid leukemia: Cytogenetic abnormalities"</a>.)</p><p></p><p class="headingAnchor" id="H1373884575"><span class="h1">PATHOBIOLOGY</span><span class="headingEndMark"> — </span>Myelodysplastic syndromes/neoplasms (MDS) are clonal neoplasms that arise from mutations in hematopoietic stem cells. Development of MDS involves a series of genetic changes in hematopoietic stem/progenitor cells, which alters their growth and differentiation and results in accumulation of abnormal, immature myeloid cells in blood and marrow that impairs normal hematopoiesis [<a href="#rid1">1,2</a>]. Driver mutations are detected in &gt;90 percent of cases of MDS. Most mutations are acquired, but some cases are related to germline (inherited) genetic abnormalities. (See <a class="local">'Acquired mutations'</a> below and <a class="local">'Pathologic germline variants'</a> below.) </p><p>The precise cause of the mutations associated with MDS is unknown for most patients, but in some cases it is associated with exposure to cytotoxic chemotherapy and/or ionizing radiation (ie, therapy-related MDS) or environmental toxins (eg, tobacco, benzene) [<a href="#rid3">3</a>]. Overall, a high fraction of acquired mutations consist of C to T substitutions, which are consistent with spontaneous deamination of cytosine, an event that occurs with clock-like regularity in hematopoietic stem cells and which may explain, at least in part, the association of MDS with aging [<a href="#rid4">4</a>].</p><p>Many cases of MDS arise in the setting of clonal hematopoiesis of indeterminate potential (CHIP). With CHIP, similar mutations are present, but the dysplasia and ineffective hematopoiesis that characterize MDS are absent [<a href="#rid5">5,6</a>]. CHIP and related hematopoietic disorders are discussed separately. (See  <a class="medical medical_review" href="/d/html/107866.html" rel="external">"Clonal hematopoiesis of indeterminate potential (CHIP) and related disorders of clonal hematopoiesis"</a>.)</p><p>Inherited genetic abnormalities may also contribute to development of MDS  (<a class="graphic graphic_table graphicRef72951" href="/d/graphic/72951.html" rel="external">table 1</a>). Although such associations were previously considered rare, routine targeted sequencing of MDS genomes has increased the identification of cases with an underlying germline predisposition. Pathologic gene variants that may cause familial MDS are discussed below. (See <a class="local">'Pathologic germline variants'</a> below.)</p><p class="headingAnchor" id="H1293715263"><span class="h1">CLASSIFICATION OF MDS</span><span class="headingEndMark"> — </span>MDSs are clonal hematopoietic neoplasms manifest as persistent cytopenias (anemia, neutropenia, and/or thrombocytopenia) accompanied by morphologic dysplasia, along with variable rates of progression to acute myeloid leukemia (AML) or bone marrow failure. </p><p>There are two contemporary classification systems for MDS; we consider use of either of the following systems acceptable for classification of individual cases:</p><p class="bulletIndent1"><span class="glyph">●</span><strong>International Consensus Classification of Myeloid Neoplasms and Acute Leukemias (ICC)</strong> – Briefly, cases of MDS are categorized according to [<a href="#rid7">7</a>]:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Specific genetic or karyotypic abnormalities</strong> – MDS with mutated <em>SF3B1</em> or del(5q) (deletion of the long arm of chromosome 5)</p><p></p><p class="bulletIndent2">or </p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Dysplasia</strong> – MDS, not otherwise specified without dysplasia, with single lineage dysplasia, or with multilineage dysplasia</p><p></p><p class="bulletIndent2">or </p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Excess blasts</strong> – MDS with excess blasts (ie, 5 to 9 percent in bone marrow or 2 to 9 percent in peripheral blood) or MDS/AML (ie, 10 to 19 percent in blood or marrow)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>World Health Organization 5</strong><strong><sup>th</sup></strong><strong> edition (WHO5) </strong>– Briefly, cases are classified according to [<a href="#rid8">8</a>]:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Defining genetic abnormalities</strong> – MDS with low blasts and isolated del(5q), <em>SF3B1</em> mutation, or biallelic <em>TP53</em> inactivation</p><p></p><p class="bulletIndent2">or</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Morphologically defined</strong> – MDS with hypoplasia (≤25 percent bone marrow cellularity, adjusted for age), MDS with low blasts (&lt;5 percent in marrow and &lt;2 percent in blood), MDS with increased blasts (stratified according to blast percentages up to &lt;20 percent), or MDS with fibrosis</p><p></p><p>Importantly, labels and diagnostic criteria for categories of MDS differ between ICC and WHO5. Furthermore, the two schemes classify therapy-related MDS, and cases associated with germline genetic abnormalities differently. Further descriptions of these systems are presented separately. (See  <a class="medical medical_review" href="/d/html/4716.html" rel="external">"Classification of hematopoietic neoplasms", section on 'Myelodysplastic neoplasms/syndromes (MDS)'</a>.)</p><p>We favor use of either the ICC or WHO5, rather than earlier nosologic schemes, because they emphasize the chromosomal and genetic aspects of MDS that contribute importantly to diagnosis, classification, prognosis, and treatment [<a href="#rid7">7,8</a>]. </p><p>Clinical presentation, evaluation, diagnosis, and prognosis of MDS are discussed separately. (See  <a class="medical medical_review" href="/d/html/4492.html" rel="external">"Clinical manifestations, diagnosis, and classification of myelodysplastic syndromes (MDS)", section on 'Diagnosis'</a> and  <a class="medical medical_review" href="/d/html/15775.html" rel="external">"Prognosis of myelodysplastic neoplasms/syndromes (MDS) in adults"</a>.)</p><p class="headingAnchor" id="H4"><span class="h1">CHROMOSOMAL ABNORMALITIES</span><span class="headingEndMark"> — </span>Approximately one-half of cases of de novo MDS (primary MDS; ie, not therapy-related or caused by germline conditions) have at least one chromosomal abnormality at the time of diagnosis. For some patients, karyotypic abnormalities first emerge during observation or treatment. </p><p class="headingAnchor" id="H2381741570"><span class="h2">Detection</span><span class="headingEndMark"> — </span>Chromosome analysis should be performed in all patients with MDS or with a clinical presentation that suggests the diagnosis. The application of chromosomal findings to the diagnosis and classification of MDS is discussed separately. (See  <a class="medical medical_review" href="/d/html/4492.html" rel="external">"Clinical manifestations, diagnosis, and classification of myelodysplastic syndromes (MDS)"</a>.)</p><p>Karyotyping (chromosomal banding) and fluorescence in situ hybridization are used to detect chromosomal abnormalities in patients with MDS. Other techniques, such as single nucleotide polymorphism microarrays or comparative genomic hybridization techniques, can detect some additional genomic and chromosomal abnormalities with greater resolution and possibly better sensitivity, but they are not widely available. Techniques for identifying genomic and chromosomal abnormalities are described separately. (See  <a class="medical medical_review" href="/d/html/4482.html" rel="external">"General aspects of cytogenetic analysis in hematologic malignancies"</a>.)</p><p class="headingAnchor" id="H256827820"><span class="h2">Recurring abnormalities</span><span class="headingEndMark"> — </span>Many of the chromosomal abnormalities associated with MDS reflect characteristic, recurrent karyotypic events  (<a class="graphic graphic_table graphicRef77909" href="/d/graphic/77909.html" rel="external">table 2</a>). Some of these abnormalities are uniquely associated with MDS and are important for diagnosis and classification of MDS, but many of the common chromosome abnormalities are also seen in acute myeloid leukemia (AML) or myeloproliferative neoplasms [<a href="#rid7">7,8</a>]. The diagnosis of MDS is excluded by detection of certain chromosomal abnormalities. (See  <a class="medical medical_review" href="/d/html/4492.html" rel="external">"Clinical manifestations, diagnosis, and classification of myelodysplastic syndromes (MDS)", section on 'Diagnosis'</a>.)</p><p>Among 2902 patients presenting with MDS, an abnormal karyotype was seen in 45 percent of cases [<a href="#rid9">9</a>]. Similarly, cytogenetic abnormalities were detected by G-banding in 41 percent of nearly 3000 cases of MDS [<a href="#rid10">10</a>]. The proportion of patients with MDS-associated chromosomal abnormalities is somewhat lower than in patients with de novo AML (ie, 70 to 80 percent), but the likelihood of karyotypic abnormalities is increased in patients with advanced MDS. Complex karyotypes are found in 10 to 15 percent of patients with primary MDS, but additional chromosomal aberrations may emerge later in the course of MDS, or an abnormal clone may emerge in a patient with a previously normal karyotype; such changes may portend progression to AML [<a href="#rid11">11</a>]. </p><p class="headingAnchor" id="H380916266"><span class="h2">Types of chromosomal abnormalities</span><span class="headingEndMark"> — </span>Most chromosomal abnormalities in MDS involve a numerical change (ie, monosomy or trisomy) or a structural abnormality of a single chromosome (eg, interstitial deletion, inversion). Complex karyotypes (ie, multiple chromosomal abnormalities) are common, particularly in cases of higher-risk MDS. A general description of chromosomal abnormalities is presented separately. (See  <a class="medical medical_review" href="/d/html/4490.html" rel="external">"Chromosomal translocations, deletions, and inversions"</a>.)</p><p>Characteristic chromosomal abnormalities in MDS include:</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Numerical and unbalanced structural abnormalities </strong>– The del(5q), -7/del(7q), +8, and del(20q) are commonly found in MDS. Loss of the Y chromosome is often seen in older males, but it is not thought to play a role in the pathogenesis of MDS. </p><p></p><p class="bulletIndent1">Except for del(5q), specific chromosomal abnormalities have not correlated with specific clinical or morphological subsets of MDS. (See <a class="local">'del(5q)'</a> below.) </p><p></p><p class="bulletIndent1">The del(5q), -7/del(7q), +8, and del(20q) are also seen in AML (especially AML that emerged from MDS), therapy-related myeloid neoplasms (t-MN; ie, AML following treatment with alkylating agents and/or radiation therapy), and in some cases of advanced stage chronic myeloid leukemia (CML).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Balanced translocations </strong>– Balanced translocations involving two distinct chromosomes are uncommon with MDS, with the following exceptions:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>t(3;21)(q26.2;q22.1)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>inv(3)(q21.3q26.2)/t(3;3)(q21.3;q26.2)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>t(11;16)(q23.3;p13.3)</p><p></p><p class="bulletIndent1">The above findings are also seen in AML with myelodysplastic features, t-MNs, and in rare cases of CML during accelerated or blast phase. </p><p></p><p class="bulletIndent1">Importantly, the following balanced translocations, which are associated with distinct subsets of AML, exclude the diagnosis of MDS [<a href="#rid7">7,8</a>]: </p><p></p><p class="bulletIndent2"><span class="glyph">•</span>t(8;21) </p><p></p><p class="bulletIndent2"><span class="glyph">•</span>inv(16)/t(16;16)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>t(15;17).</p><p></p><p class="headingAnchor" id="H256828282"><span class="h3">del(5q)</span><span class="headingEndMark"> — </span>Deletion of the long arm of chromosome 5 (5q) is the most common chromosomal abnormality in MDS, occurring in approximately 15 percent of cases overall [<a href="#rid9">9,12-14</a>]. </p><p>This lower-risk category of MDS is defined by deletion of 5q alone, or by del(5q) accompanied by only one other cytogenetic aberration, except for -7 or del(7q). This syndrome is called "MDS with del(5q)" in the International Consensus Classification of Myeloid Neoplasms and Acute Leukemias (ICC) [<a href="#rid7">7</a>] and "MDS with low blasts and isolated 5q deletion" by the WHO5 [<a href="#rid8">8</a>]. (See  <a class="medical medical_review" href="/d/html/4716.html" rel="external">"Classification of hematopoietic neoplasms", section on 'Myelodysplastic neoplasms/syndromes (MDS)'</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Clinical features</strong> – Distinctive clinical features of MDS with del(5q) include female predominance, severe macrocytic anemia, normal or elevated platelet counts with hypolobulated micromegakaryocytes, a low rate of progression to AML, and responsiveness to the immunomodulatory drug, <a class="drug drug_general" data-topicid="9822" href="/d/drug information/9822.html" rel="external">lenalidomide</a> [<a href="#rid15">15</a>]. (See  <a class="medical medical_review" href="/d/html/4542.html" rel="external">"Treatment of lower-risk myelodysplastic syndromes (MDS)", section on 'Chromosome 5q deletion'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Prognosis</strong> – Cases of MDS where del(5q) is the sole chromosomal abnormality have a relatively favorable prognosis and good chance of responding to treatment with <a class="drug drug_general" data-topicid="9822" href="/d/drug information/9822.html" rel="external">lenalidomide</a>  (<a class="graphic graphic_table graphicRef96321" href="/d/graphic/96321.html" rel="external">table 3</a>) [<a href="#rid2">2,13</a>]. (See  <a class="medical medical_review" href="/d/html/15775.html" rel="external">"Prognosis of myelodysplastic neoplasms/syndromes (MDS) in adults"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Deleted regions </strong>– Although deletions of 5q are large and interstitial (ie, two chromosomal breaks, with loss of the intervening segment), cytogenetic and molecular analysis has led to the identification of two smaller commonly deleted regions (CDRs) [<a href="#rid13">13,14,16</a>]:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>5q32-33.1</strong> – All patients with MDS with del(5q) have this region deleted. Isolated deletion of this locus is usually associated with a favorable prognosis. </p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>5q31.2</strong> – Deletion of this locus is more commonly seen with higher-risk MDS or therapy-related MDS and is frequently associated with a complex karyotype, <em>TP53</em> loss or mutation, and more aggressive disease.</p><p></p><p class="bulletIndent1">Most patients have large deletions that span both CDRs. The del(5q) is often accompanied by other chromosomal abnormalities, but association of del(5q) with loss of chromosome 7 or del(7q) excludes the diagnosis of MDS with del(5q). In each case of del(5q), the deletions occur on a single chromosome, resulting in a hemizygous (haploinsufficient) state, with retention of one normal allele of all genes within the deleted segment. Except for rare cases, no homozygous mutations of genes on 5q have been detected by gene sequencing.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Involved genes</strong> – Both protein-coding genes and microRNAs (miRNAs) that lie within 5q have been implicated in the macrocytic anemia, neutropenia, and defective immunity associated with the MDS with del(5q) [<a href="#rid2">2,14,17</a>]. Haploinsufficiency of genes on 5q appears to provide a growth advantage to affected cells, compared with wild-type cells. Among other genes, <em>RPS14, CSNK1A1, </em>and<em> miRNA-145</em> have been implicated in the pathogenesis of this disorder, although some of them may contribute only indirectly to the phenotype (eg, by activation of WNT/Beta catenin signaling or by cooperating with a <em>TP53 </em>mutation).</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Protein-encoding genes</strong> – The following genes are thought to contribute to the pathophysiology of MDS with del(5q): </p><p></p><p class="bulletIndent3"><span class="glyph">-</span><strong><em>RPS14</em></strong><strong> </strong>– The RPS14 protein, which is required for maturation of 40S ribosomal subunits, has been implicated in abnormalities of erythropoiesis and altered immunity in MDS with del(5q) [<a href="#rid13">13,14</a>]. Knock-down of <em>RPS14</em> blocked erythroid differentiation, whereas forced overexpression of RPS14 in cells from MDS patients with del(5q) rescued erythropoiesis. Haploinsufficiency of <em>RPS14</em> induces expression of other ribonucleoproteins, which can decrease MDM2 (a negative regulator of p53) and thereby activate p53 and enhance apoptosis. Loss of RPS14 may also act by increasing expression of S100 calcium-binding proteins (S100A8 and S100A9), which are involved in innate immune signaling [<a href="#rid18">18</a>]. </p><p></p><p class="bulletIndent3">Interestingly, the ribosomal processing defect caused by haploinsufficienc<em>y of RPS14</em> in MDS with del(5q) is highly analogous to the functional ribosomal defect seen in Diamond-Blackfan anemia. (See  <a class="medical medical_review" href="/d/html/5931.html" rel="external">"Overview of causes of anemia in children due to decreased red blood cell production", section on 'Diamond-Blackfan anemia'</a>.)</p><p></p><p class="bulletIndent3"><span class="glyph">-</span><strong><em>CSNK1A1</em></strong> – <em>CSNK1A1</em> encodes casein kinase 1A, a serine-threonine kinase. CSNK1A1 is a component of the APC destruction complex, which regulates WNT signaling via degradation of beta catenin (<em>CTNNB1</em>). Mutations<em> </em>in<em> CSNK1A1</em> were detected in 7 of 39 patients with MDS and del(5q) [<a href="#rid19">19</a>]. Haploinsufficiency <em>of CSNK1A1</em> enhances proliferation of del(5q) cells by decreasing inhibition of beta catenin more than it decreases inhibition of apoptosis (through de-repressed pP53) [<a href="#rid20">20</a>]. Haploinsufficiency of <em>Csnk1a1</em> in animal models led to clonal expansion and a proliferative advantage in a beta catenin-dependent manner [<a href="#rid21">21,22</a>]. </p><p></p><p class="bulletIndent3">This functional mechanism has been associated with how <a class="drug drug_general" data-topicid="9822" href="/d/drug information/9822.html" rel="external">lenalidomide</a> is effective against del(5q) cells. The direct protein target of lenalidomide is cereblon (CRBN), a component of the Cul4-based E3 ubiquitin ligase. Lenalidomide modulates CRBN function, leading to ubiquitination/degradation of specific protein substrates and it may also decrease levels of CK1A, Ikaro<em>s (IKZF1</em>) and Aiolo<em>s (IKZF3</em>) via ubiquitination [<a href="#rid23">23</a>]<em>. TP53</em> mutations have been linked to lenalidomide resistance and progression to AML in del(5q) MDS patients [<a href="#rid24">24</a>]. Hemizygous mutations in <em>CSNK1A1</em> have been reported [<a href="#rid25">25,26</a>]. </p><p></p><p class="bulletIndent3"><span class="glyph">-</span><strong>Other genes</strong> – Other hematopoiesis-related genes and tumor suppressor genes that are located in the CDR regions include <em>CTNNA1</em>, <em>PPP2CA</em>, <em>EGR1</em>, <em>TIFAB,</em> <em>SPARC</em>, and <em>CDC25C</em>, but their specific contributions to the del(5q) phenotype in MDS are not well-defined [<a href="#rid27">27</a>].</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>MicroRNAs</strong> – Haploinsufficiency of <em>miR-145 </em>and <em>miR-146a</em>, which are micro-RNAs (miRNAs) located near the <em>RPS14</em> gene and are abundant in hematopoietic stem/progenitor cells (HSPCs), may cooperate with loss of <em>RPS14</em>. The Toll-interleukin-1 receptor domain-containing adaptor protein (<em>TIRAP</em>) and tumor necrosis factor receptor-associated factor-6 (<em>TRAF6</em>) are respective targets of these miRNAs, implicating inappropriate activation of innate immune signals in the pathogenesis of MDS with del(5q) [<a href="#rid13">13</a>]. </p><p></p><p class="bulletIndent1">Studies in a mouse model suggest that a p53-dependent mechanism underlies MDS with del(5q), perhaps due to activation of the innate immune system and induction <em>of S100A8-S100A9</em> expression, leading to a p53-dependent erythroid differentiation defect [<a href="#rid28">28,29</a>]. In one report, the low expression <em>of RPS14</em> in 23 patients with MDS with del(5q) was not due to promoter hypermethylation, suggesting that the use of hypomethylating agents (eg, <a class="drug drug_general" data-topicid="8797" href="/d/drug information/8797.html" rel="external">azacitidine</a>, <a class="drug drug_general" data-topicid="8855" href="/d/drug information/8855.html" rel="external">decitabine</a>) is unlikely to benefit this MDS subset [<a href="#rid13">13</a>]. </p><p></p><p class="headingAnchor" id="H256828394"><span class="h3">Monosomy 7 and del(7q)</span><span class="headingEndMark"> — </span>Approximately 10 percent of patients with de novo MDS and up to one-half of patients with therapy-related MDS demonstrate -7 or del(7q), either alone or as part of a complex karyotype [<a href="#rid9">9</a>]. Approximately 90 percent of such cases have loss of the entire chromosome 7 (-7), while 10 percent have a del(7q) (ie, deletion of the long arm of the chromosome). Deletion of chromosome 7 in MDS is associated with adverse prognosis. (See  <a class="medical medical_review" href="/d/html/15775.html" rel="external">"Prognosis of myelodysplastic neoplasms/syndromes (MDS) in adults"</a>.)</p><p>Genes that have been implicated in the pathogenesis of MDS with chromosome 7 deletion include [<a href="#rid30">30</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span><strong><em>SAMD9/SAMD9L</em></strong><em> </em>–<em> </em>Human <em>SAMD9</em> and <em>SAMD9L</em> encode related endosomal proteins that facilitate homotypic fusion of endosomes that are critical for endosomal trafficking, including metabolism of cytokine receptors [<a href="#rid31">31</a>].</p><p></p><p class="bulletIndent1"><em>SAMD9</em> mutations also cause MIRAGE syndrome, a multisystem disorder characterized by myelodysplasia, infection, restriction of growth, adrenal hypoplasia, genital phenotypes, and enteropathy [<a href="#rid32">32</a>]. (See  <a class="medical medical_review" href="/d/html/117758.html" rel="external">"Inborn errors of immunity (primary immunodeficiencies): Classification"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong><em>EZH2</em></strong> – EZH2 is a methyltransferase that is a component of the polycomb repressive complex 2 (PRC2), which catalyzes trimethylation of lysine 27 of histone H3 (H3K27) and generally serves as a gene silencer that influences stem cell renewal by repression of genes involved in cell fate decisions [<a href="#rid33">33</a>]. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong><em>MLL3</em></strong> – MLL3 has histone methyltransferase activity for lysine 4 of histone 3 (H3K4), a histone mark that is associated with active transcription [<a href="#rid34">34</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Others</strong> – Other genes implicated in MDS with -7 include <em>CUX1</em> (a cut-like homeobox gene that is a haploinsufficient tumor suppressor gene) [<a href="#rid35">35,36</a>], <em>LUC7L2 </em>(a LUC7-like pre-mRNA splicing factor), and <em>CUL1 </em>(which encodes a spliceosomal protein) [<a href="#rid25">25</a>]. </p><p></p><p>Certain recurring gene mutations are associated with isolated -7 or del(7q) and some may have prognostic significance in MDS. In a cohort of 81 patients with MDS, AML, or other myeloid neoplasms with del(7q) as the sole abnormality, mutations of<em> ASXL1, TET2, DNMT3A, RUNX1, </em>and/o<em>r SRSF2</em> were present in 90 percent of 80 patients; the association of<em> RUNX1 </em>an<em>d ASXL1</em> mutations with AML with del(7q) was especially notable [<a href="#rid37">37</a>]. In another study, somatic mutations (most commonly<em> ASXL1, U2AF1, DNMT3A, RUNX1, EZH1, </em>an<em>d TET2</em>), were detected in 79 percent of 117 MDS patients with monosomy 7 or del(7q) as the sole abnormality [<a href="#rid38">38</a>]. In multivariate analysis, blast count,<em> TP53</em> mutations, and the number of mutations were independent predictors of overall survival; the cytogenetic subgroups did not retain prognostic relevance. (See <a class="local">'Acquired mutations'</a> below.)</p><p class="headingAnchor" id="H256828429"><span class="h3">Trisomy 8</span><span class="headingEndMark"> — </span>Trisomy 8 is seen in &lt;10 percent of patients with MDS and is considered an intermediate-risk finding [<a href="#rid39">39</a>]. Gain of chromosome 8 has been associated with higher expression of anti-apoptotic genes compared with normal cells and may provide a selective advantage over unaffected hematopoietic precursors. Overexpression of <em>MYC</em> at 8q24.2 has also been implicated in the pathogenesis of myeloid disorders with trisomy 8.</p><p class="headingAnchor" id="H256828457"><span class="h3">del(20q)</span><span class="headingEndMark"> — </span>Deletions of the long arm of chromosome 20 occur in &lt;5 percent of cases of MDS and are also seen in patients with AML and myeloproliferative disorders [<a href="#rid9">9</a>]. A study of 153 patients with MDS with del(20q), including 93 patients with del(20q) as sole abnormality, identified an association of del(20q) in MDS with <em>ASXL1</em> deletion/mutations and a poor prognosis, including short overall survival and high risk of progression to AML [<a href="#rid40">40</a>]. </p><p class="headingAnchor" id="H3851964777"><span class="h3">Other karyotypic abnormalities</span><span class="headingEndMark"> — </span>Among other chromosomal abnormalities that have been reported in MDS are [<a href="#rid41">41</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>del(13q) </p><p class="bulletIndent1"><span class="glyph">●</span>del(11q) </p><p class="bulletIndent1"><span class="glyph">●</span>del(12p) or t(12p)</p><p class="bulletIndent1"><span class="glyph">●</span>del(9q) </p><p class="bulletIndent1"><span class="glyph">●</span>idic(X)(q13) </p><p class="bulletIndent1"><span class="glyph">●</span>del(17p)/t(17p) (unbalanced translocations) or i(17q) (ie, loss of 17p)</p><p class="bulletIndent1"><span class="glyph">●</span>t(11;16)(q23.3;p13.3)</p><p class="bulletIndent1"><span class="glyph">●</span>t(3;21)(q26.2;q22.1)</p><p class="bulletIndent1"><span class="glyph">●</span>t(1;3)(p36.3;q21.3) </p><p class="bulletIndent1"><span class="glyph">●</span>t(2;11)(p21;q23.3) </p><p class="bulletIndent1"><span class="glyph">●</span>inv(3)(q21.3q26.2) </p><p class="bulletIndent1"><span class="glyph">●</span>t(6;9)(p23.3;q34.1) </p><p></p><p class="headingAnchor" id="H256819286"><span class="h1">GENE MUTATIONS</span><span class="headingEndMark"> — </span>Gene mutations are detected in nearly all patients with MDS, whether they are associated with chromosomal abnormalities or not. Although most reflect acquired mutations, pathogenic or likely-pathogenic germline variants may also be found in patients with MDS of all ages. (See <a class="local">'Pathologic germline variants'</a> below.)</p><p>Combining genomic profiling with hematologic and cytogenetic parameters has improved risk stratification of patients with MDS. (See  <a class="medical medical_review" href="/d/html/15775.html" rel="external">"Prognosis of myelodysplastic neoplasms/syndromes (MDS) in adults", section on 'Mutation-based models'</a>.)</p><p class="headingAnchor" id="H1664581150"><span class="h2">Acquired mutations</span><span class="headingEndMark"> — </span>Mutations are primarily found in genes that encode proteins that affect epigenetic regulation (eg, DNA methylation, histone modification), RNA-splicing machinery, transcription factors, and cytokine signaling pathways. Many are driver mutations that have independent prognostic significance (<em>TP53, EZH2, ETV6, RUNX1</em>, and <em>ASXL1</em>) and are associated with progression to acute myeloid leukemia (AML) [<a href="#rid2">2,42</a>]. As an example, mutations were identified in 94 percent of nearly 3000 patients with MDS; genes mutated in &gt;10 percent of cases included <em>TET2, ASXL1, SF3B1, DNMT3A, SRSF2, RUNX1, </em>and<em> TP53 </em>[<a href="#rid10">10</a>]. Other large studies have reported similar findings [<a href="#rid43">43,44</a>]. (See  <a class="medical medical_review" href="/d/html/15775.html" rel="external">"Prognosis of myelodysplastic neoplasms/syndromes (MDS) in adults", section on 'Prognostic factors'</a> and  <a class="medical medical_review" href="/d/html/4516.html" rel="external">"Acute myeloid leukemia: Risk factors and prognosis"</a>.)</p><p>Genes that have been implicated in the pathogenesis of specific cytogenetic abnormalities associated with MDS are discussed above. (See <a class="local">'Types of chromosomal abnormalities'</a> above.)</p><p>Genes that are most often mutated in MDS include [<a href="#rid2">2,42,43,45</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span><strong><em>TET2</em></strong> – DNA methylation is a prognostic marker and predictor of response to therapy among patients with MDS and appears to be a mechanism of disease progression to AML. <em>TET</em> genes encode proteins involved in the epigenetic control of DNA expression through demethylation. Somatic mutations in <em>TET2</em> occur in approximately 15 percent of myeloid cancers, and up to 30 percent of MDS [<a href="#rid43">43</a>]. Loss-of-function mutations of <em>TET2</em> result in increased methylation and silencing of genes that are normally expressed. When present in MDS, <em>TET2</em> mutations have been associated with a more favorable prognosis. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong><em>ASXL1</em></strong> – <em>ASXL1</em> encodes a protein involved in epigenetic regulation of gene expression and is mutated in 10 to 20 percent of MDS cases [<a href="#rid2">2,42,43,45</a>]. <em>ASXL1</em> mutations are associated with a decreased overall survival and shorter time to progression to AML.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong><em>SF3B1</em></strong> – The <em>SF3B1</em> gene encodes a nuclear ribonucleoprotein component of the spliceosome, which is responsible for splicing messenger RNA. Recurrent somatic point mutations in <em>SF3B1</em> are found in at least one-fifth of cases of MDS [<a href="#rid43">43</a>]. MDS with <em>SF3B1</em> mutations identifies a distinct subset of MDS that includes &gt;90 percent of cases with ≥5 percent ring sideroblasts [<a href="#rid7">7,8,46</a>]. (See <a class="local">'Classification of MDS'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong><em>DNMT3A</em></strong> – <em>DNMT3A</em>, located at 2p23, encodes a DNA methyltransferase that catalyzes addition of a methyl group to the cytosine residue of CpG dinucleotides, which are prevalent in gene promoters, thereby regulating gene expression. Mutations of <em>DNMT3A</em> have been detected in 8 to 13 percent of primary MDS patients [<a href="#rid2">2,42,43,45</a>] and associated with worse overall survival in MDS and more rapid progression to AML.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong><em>SRSF2</em></strong> – <em>SRSF2</em> at 17q25 encodes serine/arginine-rich splicing factor 2, which is critical for assembly of the spliceosome, selection of the correct splice-sites, and constitutive and alternative RNA splicing during the processing of precursor mRNA to mature mRNA. Mutations of <em>SRSF2</em> are detected in 12 to 15 percent of MDS patients [<a href="#rid47">47</a>], with a higher frequency in older adult males, and are associated with a poor prognosis.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong><em>RUNX1</em></strong> – Mutations of the transcriptional core-binding factor gene <em>RUNX1</em> are seen in 7 to 15 percent of cases of de novo MDS, are more common in cases of therapy-related MDS, and portend a poorer prognosis [<a href="#rid43">43</a>]. <em>RUNX1</em> is a translocation partner for <em>RUNX1T1</em> (ETO) in cases of AML with the t(8;21). (See  <a class="medical medical_review" href="/d/html/4544.html" rel="external">"Acute myeloid leukemia: Cytogenetic abnormalities", section on 't(8;21); RUNX1::RUNX1T1'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong><em>TP53</em></strong> – The <em>TP53</em> tumor suppressor gene, located on 17p, encodes the p53 protein (also referred to as TP53), which mediates cell cycle arrest in response to a variety of cellular stressors. In MDS, about 5 to 15 percent of cases have <em>TP53</em> mutations at the time of diagnosis, frequently in association with a del(5q) [<a href="#rid24">24,43</a>]. Abnormalities of <em>TP53</em> are more common in patients with MDS associated with prior exposure to alkylating agents or radiation (ie, therapy-related MDS). Loss of wild-type <em>TP53</em> is associated with resistance to treatment and is an independent marker of poor prognosis [<a href="#rid9">9</a>].</p><p></p><p class="bulletIndent1"><em>TP53</em> mutations are associated with adverse outcomes in patients with MDS with complex karyotype (CK). In one study,<em> TP53</em> mutations were identified in 55 percent of 359 patients with MDS-CK [<a href="#rid48">48</a>].<em> TP53</em> mutations were enriched in MDS with del(5q), and MDS with ≥5 cytogenetic abnormalities, all of which are associated with shorter overall survival. Integrative genomic analyses suggested that<em> TP53</em> mutation allelic status and variant allele frequency (VAF) may provide further precision in predicting clinical outcomes [<a href="#rid49">49</a>]. Analysis of 261 patients with MDS and<em> TP53</em> mutations reported that<em> TP53</em> deletion was associated with lower rates of response to treatment. Median<em> TP53</em> VAF was 0.39 (range, 0.01 to 0.94); higher VAF was associated with adverse prognosis and lower VAF was inversely correlated with response to hypomethylating agents.<em> TP53</em> mutations in myeloid neoplasms, including de novo and therapy-related MDS and AML, are associated with adverse prognosis, particularly in cases with complex karyotypes, multi-hit or biallelic<em> TP53</em> mutations, and high VAF status [<a href="#rid50">50-52</a>].</p><p></p><p class="bulletIndent1">Note that MDS with bi-allelic <em>TP53</em> mutations constitute distinct categories in the International Consensus Classification of Myeloid Neoplasms and Acute Leukemias (ICC) and WHO5 nosologies, described below. (See <a class="local">'MDS with mutated TP53'</a> below.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Other mutated genes</strong></p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong><em>IDH</em></strong> – Mutations in the isocitrate dehydrogenase oncogenes, <em>IDH1 </em>and<em> IDH2</em>, have been reported in some cases of MDS, result in DNA hypermethylation and alteration of gene expression, and are thought to portend a poor prognosis [<a href="#rid42">42,43</a>].</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong><em>RAS</em></strong> – The <em>RAS</em> oncogenes, <em>HRAS</em>,<em> KRAS</em>,<em> </em>and <em>NRAS</em>, are important in signal transduction and have been identified in 10 to 35 percent of cases of MDS [<a href="#rid1">1,2,42,43</a>]. Most <em>RAS</em> mutations in MDS are in <em>NRAS</em>, while <em>KRAS</em> mutations are less common. In both AML and MDS, <em>RAS</em> mutations have been reported more frequently in cases with a monocytic morphology (eg, chronic myelomonocytic leukemia). The significance of <em>RAS</em> mutations in MDS remains unclear, but <em>RAS</em> mutations are associated with MDS characterized by -7/del(7q).</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong><em>FLT3</em></strong> – While mutations of <em>FLT3</em>, which encodes the FLT3 cytokine receptor, are uncommon in MDS, they have been associated with a worse prognosis [<a href="#rid42">42</a>]. (See  <a class="medical medical_review" href="/d/html/4516.html" rel="external">"Acute myeloid leukemia: Risk factors and prognosis"</a>.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong><em>U2AF1 </em></strong>– <em>U2AF1</em>, encoding a component of the RNA splicing core complex, is mutated in about 5 to 10 percent of patients with MDS; mutations are associated with worse survival outcome and increased risk of progression to AML [<a href="#rid53">53-57</a>]. </p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong><em>ZRSR2</em></strong> – <em>ZRSR2</em>, an RNA spliceosome gene, encodes an SR-rich protein that is critical for the recognition of the 3' splice acceptor site involved in pre-mRNA splicing. <em>ZRSR2</em> is mutated in about 5 percent of patients with MDS. Because <em>ZRSR2</em> is located at Xp22.2, its effects are manifest mainly in male patients and result in loss-of-function. <em>ZRSR2</em> mutations may be associated with an unfavorable prognosis in MDS [<a href="#rid53">53-55,57</a>]. </p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>BCOR </strong><em>– BCOR is a transcription factor that</em> is a component of the polycomb repressor complex. Mutations in <em>BCOR/BCORL1</em> occur in about 5 percent of MDS and may be associated with an unfavorable outcome [<a href="#rid2">2</a>].</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong><em>STAG2</em></strong> – STAG2 is one of the cohesin complex proteins that regulate the separation of sister chromatids during cell division. Mutations of <em>STAG2</em> are the most frequent among the cohesin complex genes in myeloid neoplasms, occurring in 5 to 7 percent of MDS, and is associated with a poor prognosis [<a href="#rid2">2</a>]. </p><p></p><p class="headingAnchor" id="H4100732725"><span class="h2">MDS with mutated <i>TP53</i></span><span class="headingEndMark"> — </span>ICC and WHO5 introduced a new subtype of MDS, defined by the presence of multi-hit <em>TP53 </em>mutations (ie, both alleles are mutated or deleted), which defines a highly aggressive disease with short survival [<a href="#rid50">50,52</a>]. This subtype is labeled "MDS with biallelic <em>TP53</em> inactivation" by WHO5 [<a href="#rid8">8</a>]. In the ICC it is labeled "MDS with mutated <em>TP53</em>" and, rather than including it under MDS, it is included along with other <em>TP53</em>-mutated neoplasms in a new category (Myeloid neoplasms with mutated <em>TP53</em>) [<a href="#rid7">7</a>]. (See  <a class="medical medical_review" href="/d/html/4716.html" rel="external">"Classification of hematopoietic neoplasms", section on 'Myeloid neoplasms with mutated TP53'</a>.)</p><p></p><p>Multi-hit <em>TP53</em> can be confirmed by the presence of two or more distinct <em>TP53</em> mutations (VAF frequency ≥10 percent), or a single <em>TP53</em> mutation associated with either (1) a cytogenetic aberration involving the <em>TP53</em> locus at chromosome 17p, (2) a VAF of &gt;50 percent, or (3) copy-neutral loss of heterozygosity (CN-LOH) at the 17p <em>TP53</em> locus. In the absence of LOH information, the presence of a single <em>TP53</em> mutation in the context of any complex karyotype is considered equivalent to a multi-hit <em>TP53</em>. Complex karyotypes, del(5q), -7/del(7q), and 17p abnormalities are common in this subtype.</p><p class="headingAnchor" id="H2022501930"><span class="h2">Pathologic germline variants</span><span class="headingEndMark"> — </span>Some cases of MDS are associated with pathogenic germline gene variants. Although such associations were previously considered rare, routine targeted sequencing of MDS genomes has increased identification of cases with an underlying germline predisposition. Recognition of pathogenic germline gene variants is important for clinical management of affected individuals and family members. </p><p>Examples of inherited genetic abnormalities that may contribute to development of MDS  (<a class="graphic graphic_table graphicRef72951" href="/d/graphic/72951.html" rel="external">table 1</a>) include:</p><p class="bulletIndent1"><span class="glyph">●</span>Trisomy 21/Down syndrome</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Fanconi anemia</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Bloom syndrome</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Dyskeratosis congenita and other telomere biology disorders</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Shwachman-Diamond syndrome</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Ataxia telangiectasia</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Paroxysmal nocturnal hemoglobinuria</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Congenital neutropenia</p><p></p><p>Familial MDS has been reported in association with germline mutations <em>in RUNX1</em>,<em> ANKRD26</em>,<em> CEBPA</em>,<em> DDX41</em>,<em> ETV6</em>,<em> TERC</em>,<em> TERT</em>,<em> SRP72</em>, a<em>nd GATA2</em> [<a href="#rid58">58</a>]  (<a class="graphic graphic_table graphicRef97500" href="/d/graphic/97500.html" rel="external">table 4</a>). There are three categories of familial myeloid neoplasms associated with germline mutations:</p><p class="bulletIndent1"><span class="glyph">●</span><strong>No associated phenotype</strong> – MDS with <em>DDX41</em> mutation and AML with <em>CEBPA</em> mutation are syndromes of MDS in association with a germline disorder, but they manifest no other pre-existing disorder or organ dysfunction [<a href="#rid59">59</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Platelet disorders</strong> – Germline variants involving <em>RUNX1, ANKRD26, </em>or<em> ETV6 </em>are associated with MDS with pre-existing platelet disorders. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Other syndromes</strong> – MDS in association with other organ dysfunction syndromes include <em>GATA2</em> mutation; Fanconi anemia, dyskeratosis congenita, and other bone marrow failure syndromes; neurofibromatosis; and Down syndrome. </p><p></p><p>Familial MDS is discussed in more detail separately. (See  <a class="medical medical_review" href="/d/html/93183.html" rel="external">"Familial disorders of acute leukemia and myelodysplastic syndromes"</a>.) </p><p class="headingAnchor" id="H4225773367"><span class="h1">HIGHER-RISK MDS</span><span class="headingEndMark"> — </span>Subtypes of MDS that are characterized by increased blasts in bone marrow or blood are associated with adverse prognosis. The International Consensus Classification of Myeloid Neoplasms and Acute Leukemias (ICC) and World Health Organization 5<sup>th</sup> edition (WHO5) define, label, and categorize these subtypes differently [<a href="#rid7">7,8</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span><strong>MDS with excess blasts (MDS-EB)</strong> – MDS-EB is characterized by ≥5 percent myeloid blasts in bone marrow, ≥2 percent blasts in peripheral blood (or 1 percent documented on two occasions), or the presence of Auer rods (irrespective of blast cell count), according to the ICC [<a href="#rid7">7</a>]. This subtype is named "MDS with increased blasts" and is included in the broader category of MDS, morphologically defined by the WHO5 [<a href="#rid8">8</a>]. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>MDS/AML</strong> – The ICC applies the label, MDS/acute myeloid leukemia (AML), to cytopenic myeloid neoplasms with 10-19 percent blasts in blood or marrow; this new terminology was applied to acknowledge the biologic continuum between MDS and AML [<a href="#rid7">7</a>]. These cases are labeled "MDS with increased blasts" in WHO5 [<a href="#rid8">8</a>] (and were previously called MDS-EB-2 in WHO4R [<a href="#rid60">60</a>]). <em>TP53</em> mutations, complex karyotypes, del(5q), -7/del(7q) and 17p abnormalities are common in this subtype. (See  <a class="medical medical_review" href="/d/html/4492.html" rel="external">"Clinical manifestations, diagnosis, and classification of myelodysplastic syndromes (MDS)", section on 'Diagnosis'</a> and  <a class="medical medical_review" href="/d/html/15775.html" rel="external">"Prognosis of myelodysplastic neoplasms/syndromes (MDS) in adults"</a>.)</p><p></p><p class="headingAnchor" id="H1258402946"><span class="h1">USE OF CYTOGENETICS/MUTATIONS FOR PROGNOSIS</span><span class="headingEndMark"> — </span>Particular cytogenetic abnormalities and molecular findings are useful for predicting survival in MDS and progression to acute myeloid leukemia (AML)  (<a class="graphic graphic_table graphicRef96321" href="/d/graphic/96321.html" rel="external">table 3</a>) [<a href="#rid39">39</a>]. Chromosomal abnormalities are incorporated into each of the following prognostic scoring systems for MDS; IPSS-M also incorporates molecular findings:</p><p class="bulletIndent1"><span class="glyph">●</span><strong>International Prognostic Scoring System (IPSS)–Molecular (IPSS-M) </strong>[<a href="#rid10">10</a>]</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>IPSS–revised (IPSS-R)</strong></p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>IPSS–original (IPSS)</strong></p><p></p><p>These prognostic models and prognostic calculators are presented separately. (See  <a class="medical medical_review" href="/d/html/15775.html" rel="external">"Prognosis of myelodysplastic neoplasms/syndromes (MDS) in adults"</a>.)</p><p class="headingAnchor" id="H196106698"><span class="h1">SUMMARY</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Description</strong> – Myelodysplastic syndromes/neoplasms (MDS) are a heterogeneous group of clonal hematopoietic disorders characterized by cytopenias, dysplasia, and variable rates of progression to acute myeloid leukemia (AML) and bone marrow failure.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Classification</strong> – We favor use of either of the following contemporary classification systems for MDS; both incorporate cytogenetic and molecular findings, but details of the specific category labels and diagnostic criteria differ (see <a class="local">'Classification of MDS'</a> above):</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>International Consensus Classification (ICC) </strong></p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>World Health Organization 5</strong><strong><sup>th</sup></strong><strong> edition (WHO5)</strong></p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Chromosomal abnormalities</strong> – One-half of cases of de novo MDS have at least one chromosomal abnormality at diagnosis; other cases may acquire cytogenetic abnormalities during observation or treatment. (See <a class="local">'Chromosomal abnormalities'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Detection</strong> – Chromosomal abnormalities are generally detected by karyotyping (chromosomal banding) and/or fluorescence in situ hybridization. (See <a class="local">'Detection'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Types of abnormalities</strong> – Most chromosomal abnormalities in MDS involve a numerical change (ie, monosomy or trisomy) or structural abnormality of a single chromosome (eg, interstitial deletion, inversion); complex karyotypes (ie, multiple chromosomal abnormalities) are common. Balanced translocations are less common in MDS, but usually involve t(3;21), inv(3)/t(3;3), or t(11;16). Certain balanced translocations that are associated with AML exclude the diagnosis of MDS: t(8;21), inv(16), t(16;16), t(15;17). (See <a class="local">'Types of chromosomal abnormalities'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Chromosomal abnormalities in MDS</strong> – The most common chromosomal findings in MDS are:</p><p></p><p class="bulletIndent3"><span class="glyph">-</span><strong>del(5q)</strong> – Deletion of the long arm of chromosome 5, del(5q), is a favorable prognostic category with distinctive clinical features; genes implicated in the pathogenesis are described above. (See <a class="local">'del(5q)'</a> above.) </p><p></p><p class="bulletIndent3">However, del(5q) in the setting of MDS with excess blasts or MDS/AML, which is typically associated with a complex karyotype, is associated with a poor prognosis.</p><p></p><p class="bulletIndent3"><span class="glyph">-</span><strong>-7 or del(7q)</strong> – Monosomy 7 or del(7q) is an unfavorable prognostic finding and may be an isolated finding or in association with a complex karyotype; genes implicated in the pathogenesis are described above. (See <a class="local">'Monosomy 7 and del(7q)'</a> above.)</p><p></p><p class="bulletIndent3"><span class="glyph">-</span><strong>Others</strong> – Less common chromosomal abnormalities in MDS include trisomy 8, del(20q), and others. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Mutations</strong> – Acquired mutations are detected in nearly all cases of MDS and most often involve genes encoding epigenetic regulators, RNA-splicing machinery, transcription factors, and cytokine signaling pathways. (See <a class="local">'Acquired mutations'</a> above.)</p><p></p><p class="bulletIndent1">Less often, MDS is associated with germline variants of certain genes, such as <em>DDX41</em>, <em>CEBPA</em>, GATA2, <em>RUNX1, </em>and inherited bone marrow failure syndromes. (See <a class="local">'Pathologic germline variants'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Prognosis</strong> – Cytogenetic findings, with or without mutation analysis, are incorporated into contemporary MDS prognostic models. (See <a class="local">'Use of cytogenetics/mutations for prognosis'</a> above.)</p></div><div class="headingAnchor" id="references"><ol id="reference"><li><a class="nounderline abstract_t">Sperling AS, Gibson CJ, Ebert BL. The genetics of myelodysplastic syndrome: from clonal haematopoiesis to secondary leukaemia. Nat Rev Cancer 2017; 17:5.</a></li><li><a class="nounderline abstract_t">Ogawa S. Genetics of MDS. Blood 2019; 133:1049.</a></li><li><a class="nounderline abstract_t">Schnatter AR, Glass DC, Tang G, et al. Myelodysplastic syndrome and benzene exposure among petroleum workers: an international pooled analysis. J Natl Cancer Inst 2012; 104:1724.</a></li><li><a class="nounderline abstract_t">Welch JS, Ley TJ, Link DC, et al. The origin and evolution of mutations in acute myeloid leukemia. Cell 2012; 150:264.</a></li><li><a class="nounderline abstract_t">Genovese G, Kähler AK, Handsaker RE, et al. Clonal hematopoiesis and blood-cancer risk inferred from blood DNA sequence. N Engl J Med 2014; 371:2477.</a></li><li><a class="nounderline abstract_t">Jaiswal S, Fontanillas P, Flannick J, et al. Age-related clonal hematopoiesis associated with adverse outcomes. N Engl J Med 2014; 371:2488.</a></li><li><a class="nounderline abstract_t">Arber DA, Orazi A, Hasserjian RP, et al. International Consensus Classification of Myeloid Neoplasms and Acute Leukemias: integrating morphologic, clinical, and genomic data. Blood 2022; 140:1200.</a></li><li><a class="nounderline abstract_t">Khoury JD, Solary E, Abla O, et al. The 5th edition of the World Health Organization Classification of Haematolymphoid Tumours: Myeloid and Histiocytic/Dendritic Neoplasms. Leukemia 2022; 36:1703.</a></li><li><a class="nounderline abstract_t">Schanz J, Tüchler H, Solé F, et al. New comprehensive cytogenetic scoring system for primary myelodysplastic syndromes (MDS) and oligoblastic acute myeloid leukemia after MDS derived from an international database merge. J Clin Oncol 2012; 30:820.</a></li><li><a class="nounderline abstract_t">Bernard E, Tuechler H, Greenberg PL, et al. Molecular International Prognostic Scoring System for Myelodysplastic Syndromes. NEJM Evid 2022; 1.</a></li><li><a class="nounderline abstract_t">Jabbour E, Takahashi K, Wang X, et al. Acquisition of cytogenetic abnormalities in patients with IPSS defined lower-risk myelodysplastic syndrome is associated with poor prognosis and transformation to acute myelogenous leukemia. Am J Hematol 2013; 88:831.</a></li><li><a class="nounderline abstract_t">Jerez A, Gondek LP, Jankowska AM, et al. Topography, clinical, and genomic correlates of 5q myeloid malignancies revisited. J Clin Oncol 2012; 30:1343.</a></li><li><a class="nounderline abstract_t">List A, Ebert BL, Fenaux P. A decade of progress in myelodysplastic syndrome with chromosome 5q deletion. Leukemia 2018; 32:1493.</a></li><li><a class="nounderline abstract_t">McNerney ME, Godley LA, Le Beau MM. Therapy-related myeloid neoplasms: when genetics and environment collide. Nat Rev Cancer 2017; 17:513.</a></li><li><a class="nounderline abstract_t">List A, Dewald G, Bennett J, et al. Lenalidomide in the myelodysplastic syndrome with chromosome 5q deletion. N Engl J Med 2006; 355:1456.</a></li><li><a class="nounderline abstract_t">Ribezzo F, Snoeren IAM, Ziegler S, et al. Rps14, Csnk1a1 and miRNA145/miRNA146a deficiency cooperate in the clinical phenotype and activation of the innate immune system in the 5q- syndrome. Leukemia 2019; 33:1759.</a></li><li><a class="nounderline abstract_t">Lee JH, List A, Sallman DA. Molecular pathogenesis of myelodysplastic syndromes with deletion 5q. Eur J Haematol 2019; 102:203.</a></li><li><a class="nounderline abstract_t">Schneider RK, Schenone M, Ferreira MV, et al. Rps14 haploinsufficiency causes a block in erythroid differentiation mediated by S100A8 and S100A9. Nat Med 2016; 22:288.</a></li><li><a class="nounderline abstract_t">Smith AE, Kulasekararaj AG, Jiang J, et al. CSNK1A1 mutations and isolated del(5q) abnormality in myelodysplastic syndrome: a retrospective mutational analysis. Lancet Haematol 2015; 2:e212.</a></li><li><a class="nounderline abstract_t">Boultwood J, Pellagatti A, Cattan H, et al. Gene expression profiling of CD34+ cells in patients with the 5q- syndrome. Br J Haematol 2007; 139:578.</a></li><li><a class="nounderline abstract_t">Stalmann USA, Ticconi F, Snoeren IAM, et al. Genetic barcoding systematically compares genes in del(5q) MDS and reveals a central role for CSNK1A1 in clonal expansion. Blood Adv 2022; 6:1780.</a></li><li><a class="nounderline abstract_t">Schneider RK, Ademà V, Heckl D, et al. Role of casein kinase 1A1 in the biology and targeted therapy of del(5q) MDS. Cancer Cell 2014; 26:509.</a></li><li><a class="nounderline abstract_t">Fink EC, Ebert BL. The novel mechanism of lenalidomide activity. Blood 2015; 126:2366.</a></li><li><a class="nounderline abstract_t">Jädersten M, Saft L, Smith A, et al. TP53 mutations in low-risk myelodysplastic syndromes with del(5q) predict disease progression. J Clin Oncol 2011; 29:1971.</a></li><li><a class="nounderline abstract_t">Hosono N, Makishima H, Jerez A, et al. Recurrent genetic defects on chromosome 7q in myeloid neoplasms. Leukemia 2014; 28:1348.</a></li><li><a class="nounderline abstract_t">Adema V, Palomo L, Walter W, et al. Pathophysiologic and clinical implications of molecular profiles resultant from deletion 5q. EBioMedicine 2022; 80:104059.</a></li><li><a class="nounderline abstract_t">Hosono N, Makishima H, Mahfouz R, et al. Recurrent genetic defects on chromosome 5q in myeloid neoplasms. Oncotarget 2017; 8:6483.</a></li><li><a class="nounderline abstract_t">Zambetti NA, Ping Z, Chen S, et al. Mesenchymal Inflammation Drives Genotoxic Stress in Hematopoietic Stem Cells and Predicts Disease Evolution in Human Pre-leukemia. Cell Stem Cell 2016; 19:613.</a></li><li><a class="nounderline abstract_t">Basiorka AA, McGraw KL, Eksioglu EA, et al. The NLRP3 inflammasome functions as a driver of the myelodysplastic syndrome phenotype. Blood 2016; 128:2960.</a></li><li><a class="nounderline abstract_t">Inaba T, Honda H, Matsui H. The enigma of monosomy 7. Blood 2018; 131:2891.</a></li><li><a class="nounderline abstract_t">Nagamachi A, Matsui H, Asou H, et al. Haploinsufficiency of SAMD9L, an endosome fusion facilitator, causes myeloid malignancies in mice mimicking human diseases with monosomy 7. Cancer Cell 2013; 24:305.</a></li><li><a class="nounderline abstract_t">Narumi S, Amano N, Ishii T, et al. SAMD9 mutations cause a novel multisystem disorder, MIRAGE syndrome, and are associated with loss of chromosome 7. Nat Genet 2016; 48:792.</a></li><li><a class="nounderline abstract_t">Rinke J, Chase A, Cross NCP, et al. EZH2 in Myeloid Malignancies. Cells 2020; 9.</a></li><li><a class="nounderline abstract_t">Herz HM, Hu D, Shilatifard A. Enhancer malfunction in cancer. Mol Cell 2014; 53:859.</a></li><li><a class="nounderline abstract_t">Wong CC, Martincorena I, Rust AG, et al. Inactivating CUX1 mutations promote tumorigenesis. Nat Genet 2014; 46:33.</a></li><li><a class="nounderline abstract_t">Jotte MRM, McNerney ME. The significance of CUX1 and chromosome 7 in myeloid malignancies. Curr Opin Hematol 2022; 29:92.</a></li><li><a class="nounderline abstract_t">Hartmann L, Haferlach C, Meggendorfer M, et al. Myeloid malignancies with isolated 7q deletion can be further characterized by their accompanying molecular mutations. Genes Chromosomes Cancer 2019; 58:698.</a></li><li><a class="nounderline abstract_t">Crisà E, Kulasekararaj AG, Adema V, et al. Impact of somatic mutations in myelodysplastic patients with isolated partial or total loss of chromosome 7. Leukemia 2020; 34:2441.</a></li><li><a class="nounderline abstract_t">Greenberg PL, Tuechler H, Schanz J, et al. Revised international prognostic scoring system for myelodysplastic syndromes. Blood 2012; 120:2454.</a></li><li><a class="nounderline abstract_t">Martín I, Villamón E, Abellán R, et al. Myelodysplastic syndromes with 20q deletion: incidence, prognostic value and impact on response to azacitidine of ASXL1 chromosomal deletion and genetic mutations. Br J Haematol 2021; 194:708.</a></li><li class="breakAll">World health organization classification of tumours of haematopoietic and lymphoid tissues, revised 4th edition, Swerdlow SH, Campo E, Harris NL, et al. (Eds), IARC, Lyon 2017.</li><li><a class="nounderline abstract_t">Kennedy JA, Ebert BL. Clinical Implications of Genetic Mutations in Myelodysplastic Syndrome. J Clin Oncol 2017; 35:968.</a></li><li><a class="nounderline abstract_t">Haferlach T, Nagata Y, Grossmann V, et al. Landscape of genetic lesions in 944 patients with myelodysplastic syndromes. Leukemia 2014; 28:241.</a></li><li><a class="nounderline abstract_t">Bejar R, Stevenson K, Abdel-Wahab O, et al. Clinical effect of point mutations in myelodysplastic syndromes. N Engl J Med 2011; 364:2496.</a></li><li><a class="nounderline abstract_t">Mossner M, Jann JC, Wittig J, et al. Mutational hierarchies in myelodysplastic syndromes dynamically adapt and evolve upon therapy response and failure. Blood 2016; 128:1246.</a></li><li><a class="nounderline abstract_t">Malcovati L, Stevenson K, Papaemmanuil E, et al. SF3B1-mutant MDS as a distinct disease subtype: a proposal from the International Working Group for the Prognosis of MDS. Blood 2020; 136:157.</a></li><li><a class="nounderline abstract_t">Wu SJ, Kuo YY, Hou HA, et al. The clinical implication of SRSF2 mutation in patients with myelodysplastic syndrome and its stability during disease evolution. Blood 2012; 120:3106.</a></li><li><a class="nounderline abstract_t">Haase D, Stevenson KE, Neuberg D, et al. TP53 mutation status divides myelodysplastic syndromes with complex karyotypes into distinct prognostic subgroups. Leukemia 2019; 33:1747.</a></li><li><a class="nounderline abstract_t">Montalban-Bravo G, Kanagal-Shamanna R, Benton CB, et al. Genomic context and TP53 allele frequency define clinical outcomes in TP53-mutated myelodysplastic syndromes. Blood Adv 2020; 4:482.</a></li><li><a class="nounderline abstract_t">Weinberg OK, Siddon A, Madanat YF, et al. TP53 mutation defines a unique subgroup within complex karyotype de novo and therapy-related MDS/AML. Blood Adv 2022; 6:2847.</a></li><li><a class="nounderline abstract_t">Grob T, Al Hinai ASA, Sanders MA, et al. Molecular characterization of mutant TP53 acute myeloid leukemia and high-risk myelodysplastic syndrome. Blood 2022; 139:2347.</a></li><li><a class="nounderline abstract_t">Bernard E, Nannya Y, Hasserjian RP, et al. Implications of TP53 allelic state for genome stability, clinical presentation and outcomes in myelodysplastic syndromes. Nat Med 2020; 26:1549.</a></li><li><a class="nounderline abstract_t">Makishima H, Visconte V, Sakaguchi H, et al. Mutations in the spliceosome machinery, a novel and ubiquitous pathway in leukemogenesis. Blood 2012; 119:3203.</a></li><li><a class="nounderline abstract_t">Damm F, Kosmider O, Gelsi-Boyer V, et al. Mutations affecting mRNA splicing define distinct clinical phenotypes and correlate with patient outcome in myelodysplastic syndromes. Blood 2012; 119:3211.</a></li><li><a class="nounderline abstract_t">Yoshida K, Sanada M, Shiraishi Y, et al. Frequent pathway mutations of splicing machinery in myelodysplasia. Nature 2011; 478:64.</a></li><li><a class="nounderline abstract_t">Graubert TA, Shen D, Ding L, et al. Recurrent mutations in the U2AF1 splicing factor in myelodysplastic syndromes. Nat Genet 2011; 44:53.</a></li><li><a class="nounderline abstract_t">Thol F, Kade S, Schlarmann C, et al. Frequency and prognostic impact of mutations in SRSF2, U2AF1, and ZRSR2 in patients with myelodysplastic syndromes. Blood 2012; 119:3578.</a></li><li><a class="nounderline abstract_t">Brown AL, Churpek JE, Malcovati L, et al. Recognition of familial myeloid neoplasia in adults. Semin Hematol 2017; 54:60.</a></li><li><a class="nounderline abstract_t">Polprasert C, Schulze I, Sekeres MA, et al. Inherited and Somatic Defects in DDX41 in Myeloid Neoplasms. Cancer Cell 2015; 27:658.</a></li><li><a class="nounderline abstract_t">Arber DA, Orazi A, Hasserjian R, et al. The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia. Blood 2016; 127:2391.</a></li></ol></div><div id="topicVersionRevision">Topic 4483 Version 29.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27834397" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : The genetics of myelodysplastic syndrome: from clonal haematopoiesis to secondary leukaemia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30670442" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : Genetics of MDS.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23111193" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : Myelodysplastic syndrome and benzene exposure among petroleum workers: an international pooled analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22817890" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : The origin and evolution of mutations in acute myeloid leukemia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25426838" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : Clonal hematopoiesis and blood-cancer risk inferred from blood DNA sequence.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25426837" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : Age-related clonal hematopoiesis associated with adverse outcomes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35767897" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : International Consensus Classification of Myeloid Neoplasms and Acute Leukemias: integrating morphologic, clinical, and genomic data.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35732831" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : The 5th edition of the World Health Organization Classification of Haematolymphoid Tumours: Myeloid and Histiocytic/Dendritic Neoplasms.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22331955" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : New comprehensive cytogenetic scoring system for primary myelodysplastic syndromes (MDS) and oligoblastic acute myeloid leukemia after MDS derived from an international database merge.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : Molecular International Prognostic Scoring System for Myelodysplastic Syndromes</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23760779" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : Acquisition of cytogenetic abnormalities in patients with IPSS defined lower-risk myelodysplastic syndrome is associated with poor prognosis and transformation to acute myelogenous leukemia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22370328" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : Topography, clinical, and genomic correlates of 5q myeloid malignancies revisited.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29445113" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : A decade of progress in myelodysplastic syndrome with chromosome 5q deletion.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28835720" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : Therapy-related myeloid neoplasms: when genetics and environment collide.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17021321" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : Lenalidomide in the myelodysplastic syndrome with chromosome 5q deletion.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30651631" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : Rps14, Csnk1a1 and miRNA145/miRNA146a deficiency cooperate in the clinical phenotype and activation of the innate immune system in the 5q- syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30578738" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : Molecular pathogenesis of myelodysplastic syndromes with deletion 5q.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26878232" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : Rps14 haploinsufficiency causes a block in erythroid differentiation mediated by S100A8 and S100A9.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26688096" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : CSNK1A1 mutations and isolated del(5q) abnormality in myelodysplastic syndrome: a retrospective mutational analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17916100" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : Gene expression profiling of CD34+ cells in patients with the 5q- syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35016204" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : Genetic barcoding systematically compares genes in del(5q) MDS and reveals a central role for CSNK1A1 in clonal expansion.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25242043" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : Role of casein kinase 1A1 in the biology and targeted therapy of del(5q) MDS.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26438514" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : The novel mechanism of lenalidomide activity.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21519010" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : TP53 mutations in low-risk myelodysplastic syndromes with del(5q) predict disease progression.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24429498" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : Recurrent genetic defects on chromosome 7q in myeloid neoplasms.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35617825" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : Pathophysiologic and clinical implications of molecular profiles resultant from deletion 5q.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28031539" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : Recurrent genetic defects on chromosome 5q in myeloid neoplasms.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27666011" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : Mesenchymal Inflammation Drives Genotoxic Stress in Hematopoietic Stem Cells and Predicts Disease Evolution in Human Pre-leukemia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27737891" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : The NLRP3 inflammasome functions as a driver of the myelodysplastic syndrome phenotype.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29615405" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : The enigma of monosomy 7.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24029230" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : Haploinsufficiency of SAMD9L, an endosome fusion facilitator, causes myeloid malignancies in mice mimicking human diseases with monosomy 7.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27182967" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : SAMD9 mutations cause a novel multisystem disorder, MIRAGE syndrome, and are associated with loss of chromosome 7.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32650416" id="rid32" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>33 : EZH2 in Myeloid Malignancies.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24656127" id="rid33" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>34 : Enhancer malfunction in cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24316979" id="rid34" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>35 : Inactivating CUX1 mutations promote tumorigenesis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35084368" id="rid35" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>36 : The significance of CUX1 and chromosome 7 in myeloid malignancies.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30994218" id="rid36" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>37 : Myeloid malignancies with isolated 7q deletion can be further characterized by their accompanying molecular mutations.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32066866" id="rid37" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>38 : Impact of somatic mutations in myelodysplastic patients with isolated partial or total loss of chromosome 7.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22740453" id="rid38" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>39 : Revised international prognostic scoring system for myelodysplastic syndromes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34296432" id="rid39" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>40 : Myelodysplastic syndromes with 20q deletion: incidence, prognostic value and impact on response to azacitidine of ASXL1 chromosomal deletion and genetic mutations.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34296432" id="rid40" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>41 : Myelodysplastic syndromes with 20q deletion: incidence, prognostic value and impact on response to azacitidine of ASXL1 chromosomal deletion and genetic mutations.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28297619" id="rid41" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>42 : Clinical Implications of Genetic Mutations in Myelodysplastic Syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24220272" id="rid42" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>43 : Landscape of genetic lesions in 944 patients with myelodysplastic syndromes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21714648" id="rid43" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>44 : Clinical effect of point mutations in myelodysplastic syndromes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27268087" id="rid44" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>45 : Mutational hierarchies in myelodysplastic syndromes dynamically adapt and evolve upon therapy response and failure.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32347921" id="rid45" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>46 : SF3B1-mutant MDS as a distinct disease subtype: a proposal from the International Working Group for the Prognosis of MDS.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22932795" id="rid46" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>47 : The clinical implication of SRSF2 mutation in patients with myelodysplastic syndrome and its stability during disease evolution.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30635634" id="rid47" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>48 : TP53 mutation status divides myelodysplastic syndromes with complex karyotypes into distinct prognostic subgroups.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32027746" id="rid48" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>49 : Genomic context and TP53 allele frequency define clinical outcomes in TP53-mutated myelodysplastic syndromes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35073573" id="rid49" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>50 : TP53 mutation defines a unique subgroup within complex karyotype de novo and therapy-related MDS/AML.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35108372" id="rid50" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>51 : Molecular characterization of mutant TP53 acute myeloid leukemia and high-risk myelodysplastic syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32747829" id="rid51" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>52 : Implications of TP53 allelic state for genome stability, clinical presentation and outcomes in myelodysplastic syndromes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22323480" id="rid52" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>53 : Mutations in the spliceosome machinery, a novel and ubiquitous pathway in leukemogenesis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22343920" id="rid53" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>54 : Mutations affecting mRNA splicing define distinct clinical phenotypes and correlate with patient outcome in myelodysplastic syndromes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21909114" id="rid54" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>55 : Frequent pathway mutations of splicing machinery in myelodysplasia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22158538" id="rid55" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>56 : Recurrent mutations in the U2AF1 splicing factor in myelodysplastic syndromes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22389253" id="rid56" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>57 : Frequency and prognostic impact of mutations in SRSF2, U2AF1, and ZRSR2 in patients with myelodysplastic syndromes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28637618" id="rid57" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>58 : Recognition of familial myeloid neoplasia in adults.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25920683" id="rid58" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>59 : Inherited and Somatic Defects in DDX41 in Myeloid Neoplasms.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27069254" id="rid59" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>60 : The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia.</p>
</a>
</div>
</div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
